

Share reference data

ISIN	DE000A0LD6E6
WKN	A0LD6E
Kürzel Bloomberg	GXI
Kürzel Reuters	GXIG.DE
Stock index membership	MDAX, CDAX, HDAX, Prime All Share, Classic All Share, EURO STOXX TMI, Russell Global Small Cap Growth Index and further sector and size indexes
Listings	Berlin, Duesseldorf, Frankfurt (Xetra & floor trading), Hamburg, Hanover, Munich, Stuttgart

Shareholder structure by region

Top 25 Investors


United Kingdom 22 %

Germany 9 %

Other 19 %

Netherlands 19 %

North America 31 %



Gerresheimer shares: key data

	2016	2015
Number of shares at reporting date in million	31.4	31.4
Share price ¹⁾ at reporting date in EUR	68.85	73.90
Market capitalization at reporting date in EUR m	2,161.9	2,320.5
Share price high ¹⁾ during reporting period in EUR	76.86	76.32
Share price low ¹⁾ during reporting period in EUR	57.10	41.99
Earnings per share in EUR	3.87	3.32
Adjusted earnings per share ²⁾ in EUR	4.22	3.41
Dividend per share in EUR	1.05 ³⁾	0.85

¹⁾ Xetra closing price.

²⁾ Adjusted net income after non-controlling interests divided by 31.4 m shares.

³⁾ Proposed appropriation of net earnings.



Our Vision

Gerresheimer will become the leading global partner for enabling solutions that improve health and well-being.

Our success is driven by the passion of our people.

Our Mission

We will achieve our vision by:

- understanding our customers and providing them with solutions to both their present and future needs
- living our commitment to excellent quality and continuous innovation
- leveraging our competence and technological leadership by acting as one global team
- becoming a preferred employer with highly motivated and passionate employees all over the world and, in so doing, by
- expanding our global reach and creating profitable and sustainable growth

Our Values

Integrity Innovation Teamwork
 Excellence Responsibility


Corporate responsibility is firmly anchored in our vision, mission and our values. We act in accordance with these principles at all our worldwide sites, and we take a holistic approach to sustainability. In addition to social and economic sustainability, we are particularly committed to the protection of the environment.

At Gerresheimer, environmental protection goes hand in hand with the efficient use of energy. We optimize energy usage by regularly overhauling and renewing our energy-intensive equipment such as the furnaces at our molded glass facilities.

The goals, strategies and success of our environmental initiatives and actions are regularly published as a result of our participation in the Carbon Disclosure Project (CDP). The goal of our environment strategy is to decrease the emissions to revenue ratio.

www.gerresheimer.com/en/company/corporate-responsibility.html

Clear improvement in CO₂ emissions relative to revenues (t/EUR k)



24/7 production

Our production lines never stand still. They are in operation 24 hours a day, 7 days a week. Yet we never lose focus of our responsibility as manufacturer of packaging for special pharmaceutical products.

International work environment

We offer a professional and challenging work environment in a continuously growing market at our sites in Europe, North and South America and Asia.

Tradition, experience and continuity

We are a company with a long tradition and therefore outstanding competence and extensive experience. Long-serving employees are a reflection of our workforce's loyalty to our organization.

Health and well-being

As an internationally leading partner to the pharma and healthcare industries we want to make a contribution to improving health and well-being.

Opportunities and support

We make targeted investments in our employees with the aim of offering the right career opportunities to people who know what they want and have the passion and determination to achieve it.

www.gerresheimer.com/en/careers



Short Profile

Overview

Gerresheimer is a leading global partner

... to the pharma and healthcare industry. With our specialty glass and plastic products, we contribute to health and well-being. We have worldwide operations and about 10,000 employees manufacture our products in local markets, close to our customers. With our plants in Europe, North America, South America and Asia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: Insulin pens, inhalers, prefilled syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Management Board



Prof. Dr. Christian Fischer
Chief Executive Officer



Rainer Beaujean
Chief Financial Officer



Andreas Schütte

Primary Packaging Glass Division

Plastics & Devices Division

Our Divisions



Plastics & Devices

The product portfolio of the Plastics & Devices Division includes complex, customer-specific products for the simple and safe administration of medicines, such as insulin pens, inhalers and prefilled syringes. Also included are diagnostics and medical technology products such as lancets and test systems, as well as pharmaceutical plastic containers for liquid and solid medicines with closure and safety systems. For the North American prescription retail market a complete line of regulatory compliant prescription containers for medication dispensing is available.



Primary Packaging Glass

The Primary Packaging Glass Division produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons and cream jars.

Our Products



... are important



and convenient



solutions for everyday life.



Our Locations

USA



LATIN-AMERICA

EUROPE



ASIA



Our Customers

Gerresheimer has developed longstanding relationships with customers of all sizes around the world. Our customer base includes both international and national pharmaceutical companies, American pharmacies as well as companies in the diagnostic and medical technology industries. We also supply numerous cosmetic customers with our products.

Gerresheimer in figures


Revenues by market segment

Consolidated revenues 2016: EUR 1,375.5 Mio.

Pharma and Healthcare 83 %

Cosmetic 12 %

Other 5 %



Revenues by economic area

Europe 33 %

(excl. Germany, Kazakhstan, Poland, Romania, Russia and Turkey)

Other 2 %


Emerging Markets 15 %

(Quintiles IMS definition)

Americas 26 %

(excl. Argentina, Brazil, Chile, Colombia and Mexico)

Germany 24 %



Employees by region

Europe 19 %

(excl. Germany, Kazakhstan, Poland, Romania, Russia and Turkey)


Germany 34 %

Americas 11 %

(excl. Argentina, Brazil, Chile, Colombia and Mexico)

Emerging Markets 36 %

(Quintiles IMS definition)



Group Key Figures

Financial Year end November 30 (IFRS) ¹⁾ in EUR million	FY 2016	FY 2015	Change in % ⁷⁾
Revenues organic ²⁾	1,375.5	1,282.9	+7.2
Adjusted EBITDA ³⁾ in % of revenues	307.8 22.4	262.6 20.5	+17.2 +190 bps
Net income	168.2	112.7	+49.3
of which attributable to shareholders of Gerresheimer AG	121.6	104.2	+16.7
of which attributable to non-controlling interests	46.6	8.4	>+100
Adjusted net income ⁴⁾ after non-controlling interests	132.6	107.0	+23.8
Adjusted earnings per share ⁵⁾ after non-controlling interests in EUR	4.22	3.41	+23.8
Dividend per share in EUR	1.05 ⁶⁾	0.85	+23.5
Equity ratio in %	32.1	28.9	+320 bps
Net financial debt	788.2	877.5	-10.2
Capital expenditure	113.2	125.8	-10.1

¹⁾ As of October 31, 2016, Gerresheimer sold its Life Science Research Division – the laboratory glassware business. In accordance with International Financial Reporting Standards (IFRS), the division is therefore classified as a discontinued operation. In simple terms, from the time of classification as a discontinued operation, all income and expense items in the consolidated income statement are adjusted for the current year and retrospectively for all comparative periods to be reported upon and are shown in a separate item.

²⁾ Organic: Adjusted for currency effects (which are generally translation effects) and acquisitions/divestments.

³⁾ Adjusted EBITDA: Earnings before income taxes, net finance expense, amortization of fair value adjustments, depreciation and amortization, impairment losses, restructuring expenses and one-off income and expenses.

⁴⁾ Adjusted net income: Consolidated net income before non-cash amortization of fair value adjustments, restructuring expenses, impairment losses, one-off income and expenses (including significant non-cash expenses) and the related tax effects.

⁵⁾ Based on 31.4 m shares.

⁶⁾ Proposed appropriation of net earnings.

⁷⁾ The change has been calculated on a EUR k basis.

